Completed PHASE4 INTERVENTIONAL 2-arm NCT01314781

Therapy of the Overactive Bladder Syndrome (TOBS)

Comparison of Solifenacin Combined With Pelvic Floor Muscle and Whole Body Vibration Training With Solifenacin Alone in Patients With Overactive Bladder Syndrome. - A Prospective Randomized Parallel Group Trial

Sponsor: Astellas Pharma Inc

Conditions Overactive Bladder

Interventions PFMT and WBVT solifenacin

Updated 5 times since 2017 Last updated: May 19, 2016 Started: Jan 31, 2012 Primary completion: Jan 31, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Overactive Bladder, this trial is completed. The trial is conducted by Astellas Pharma Inc and has accumulated 5 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Cantonal Hospital, Frauenfeld

Data source: Cantonal Hospital, Frauenfeld

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Frauenfeld, Switzerland